Jasper Therapeutics, Inc. a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117), as well as novel stem cell transplant conditioning regimes, appointed two pharma industry veteran executives to its regulatory affairs, quality, and clinical operations leadership teams. Patricia Carlos joins the company as senior vice president of regulatory affairs and quality, and Annette Marcantonio, was appointed vice president of clinical operati...